Wave Life Sciences (WVE) drew investor attention after reporting first quarter 2026 results, with sales of US$38.25 million, a net loss of US$26.09 million, and progress across several RNA based clinical programs.

Despite the earnings beat and clinical updates, the recent 7.17% 1 month share price return to US$7.32 comes after a much steeper 43.43% 3 month share price decline. The 3 year total shareholder return of 83.46% contrasts with a 9.63% 1 year total shareholder loss, suggesting longer term holders remain ahead even as near term momentum has softened.

If this kind of biotech news has your attention, it can be useful to scan other healthcare names working with AI in medicine using our dedicated screener for 33 healthcare AI stocks

With Wave now posting higher quarterly sales, a narrower loss, and active RNA programs, the question for you is simple: is the recent share price slide an opening, or is the market already pricing in future growth?

Most Popular Narrative: 78.5% Undervalued

Analysts following Wave Life Sciences see a fair value of $34.06 against a last close of $7.32, with their story hinging on future RNA pipeline progress and projected earnings power rather than current profits.

The upcoming clinical data readouts for key programs (AATD with WVE-006 and obesity with WVE-007) in late 2025 and early 2026 represent potential inflection points, supported by strong early efficacy and favorable safety, and, if positive, could significantly expand revenue opportunities in large, underserved markets driven by an aging population and rising chronic disease prevalence.

Want to see what backs up that confidence? The most followed storyline leans on rapid revenue expansion, margin repair, and a future earnings multiple that is anything but modest.

Result: Fair Value of $34.06 (UNDERVALUED)

However, that upbeat story runs alongside real pressure from widening losses and heavy dependence on a few clinical programs and milestone payments that may not materialise.

Another View: Price To Sales Sends A Different Signal

The analyst fair value of $34.06 suggests upside from the current $7.32 share price; however, the current P/S of 19.6x is far above both the US Pharmaceuticals average of 5.2x and a fair ratio of 0.6x. That gap points to valuation risk rather than a clear bargain. The key question is which signal matters more for you.

Next Steps

Curious whether the optimism or the concerns resonate more with you? Take a moment to assess both sides and weigh the 1 key reward and 4 important warning signs.

Looking for more investment ideas?

If Wave has sharpened your focus, do not stop here. Broaden your watchlist with other ideas that match your risk tolerance and return goals.

• Target potential mispricings by scanning 51 high quality undervalued stocks that combine quality fundamentals with attractive entry points.
• Strengthen your income stream by reviewing 13 dividend fortresses built around companies with higher yields.
• Prioritise resilience by checking 67 resilient stocks with low risk scores designed to highlight businesses with lower risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.